TAT 2016
 
Tuesday, March 22, 2016
8:50 am - 10:20 amPlenary Session 5: Immuno-oncology (2)
Chair: Antoine Italiano, Institut Bergonié
Chair: Filip Janku, MD Anderson Cancer Center
8:51 am - 9:10 amO5.1 Curative potential of T-cell immunotherapy for cancer
Speaker: Steven Rosenberg, National Cancer Institute
9:10 am - 9:30 amO5.3 Mechanisms of immune exclusion and combination approaches to overcome the non-T cell-inflamed tumor microenvironment
Speaker: Jason Luke, University of Chicago
9:30 am - 9:45 amO5.4 A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys
Speaker: Madelon Wentink, VU University Medical Center
9:45 am - 10:00 amO5.5 Phase II study of pembrolizumab in patients with recurrent thymic carcinoma
Speaker: Giuseppe Giaccone, Georgetown University
10:00 am - 10:20 amGeneral discussion
10:20 am - 10:45 amBreak




10:45 am - 12:15 pmPlenary Session 6: Targeting Difficult Targets
Chair: Geoffrey Shapiro, Dana-Farber Cancer Institute
Chair: Donald Bottaro, National Cancer Institute
10:46 am - 11:00 amO6.1 Targeting RAS, MYC, and p53: Tough Nuts to Crack
Speaker: Gary Schwartz, Columbia University Medical Center
11:00 am - 11:20 amO6.2 Targeting KRAS on multiple fronts: Drug discovery efforts at Frederick National Laboratory for Cancer Research
Speaker: Matthew Holderfield, Frederick National Laboratory for Cancer Research
11:20 am - 11:40 amO6.3 APR-246 - Restoration of mutant p53 function
Speaker: John Green, University of Liverpool
11:40 am - 12:00 pmO6.4 Targeting transcription factor MYC
Speaker: Geoffrey Shapiro, Dana-Farber Cancer Institute
12:00 pm - 12:15 pmGeneral discussion
12:15 pm - 1:15 pmLunch
12:15 pm - 1:15 pmMeet-the-professor session: How to give a talk and how to write a paper
Lee Ellis, MD Anderson Cancer Center


1:15 pm - 2:55 pmPlenary Session 7: Cell Cycle and DNA Targets
Chair: Michael Pishvaian, Georgetown University
Chair: Hilary Calvert, UCL Cancer Institute
1:16 pm - 1:35 pmO7.1 Expanding the role of cell cycle inhibitors through combination therapy
Speaker: Michael Pishvaian, Georgetown University
1:35 pm - 1:55 pmO7.2 New BET inhibitors an overview
Speaker: Patricia LoRusso, Yale Cancer Center
1:55 pm - 2:15 pmO7.3 Phase 1 study of tazemetostat (EPZ-6438), an inhibitor of EZH2: Preliminary safety and efficacy in patients with non-Hodgkin lymphoma and solid tumors
Speaker: Jean-Charles Soria, Cancer Institute Gustave Roussy
2:15 pm - 2:35 pmO7.4 DNA repair targets beyond PARP
Speaker: Ruth Plummer, Newcastle University
2:35 pm - 2:55 pmGeneral discussion
2:55 pm - 3:20 pmBreak


3:20 pm - 5:00 pmPlenary Session 8: Drug penetration into the Central Nervous System
Chair: Susan Bates, Columbia University Medical Center
Chair: Antoine Italiano, Institut Bergonié
3:21 pm - 3:40 pmO8.1 Basic biology of drug distribution in the central nervous system (CNS) and CNS metastases
Speaker: Quentin Smith, Texas Tech University Health Sciences Center
3:40 pm - 4:00 pmO8.2 Tyrosine kinase inhibitors and brain metastases: the examples of AZD9291 and AZD3759
Speaker: Jean-Charles Soria, Cancer Institute Gustave Roussy
4:00 pm - 4:20 pmO8.3 18F-FLT-PET and MRI In Assessing Responses to ANG10005 for Breast Cancer Brain Metastases
Speaker: Susan Bates, Columbia University Medical Center
4:20 pm - 4:40 pmO8.4 Immunotherapies and brain metastases
Speaker: Fabio Iwamoto, Columbia University Medical Center
4:40 pm - 5:00 pmGeneral discussion